Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Champions Oncology (CSBR) over the last 16 years, with Q4 2025 value amounting to $2000.0.

  • Champions Oncology's Capital Expenditures fell 9787.23% to $2000.0 in Q4 2025 from the same period last year, while for Oct 2025 it was $583000.0, marking a year-over-year increase of 21857.92%. This contributed to the annual value of $389000.0 for FY2025, which is 5346.89% down from last year.
  • Latest data reveals that Champions Oncology reported Capital Expenditures of $2000.0 as of Q4 2025, which was down 9787.23% from $286000.0 recorded in Q3 2025.
  • Champions Oncology's 5-year Capital Expenditures high stood at $1.2 million for Q1 2021, and its period low was -$39000.0 during Q2 2025.
  • Over the past 5 years, Champions Oncology's median Capital Expenditures value was $506000.0 (recorded in 2022), while the average stood at $464526.3.
  • In the last 5 years, Champions Oncology's Capital Expenditures surged by 60350.88% in 2021 and then tumbled by 120000.0% in 2025.
  • Champions Oncology's Capital Expenditures (Quarter) stood at $566000.0 in 2021, then rose by 6.71% to $604000.0 in 2022, then plummeted by 86.92% to $79000.0 in 2023, then grew by 18.99% to $94000.0 in 2024, then crashed by 97.87% to $2000.0 in 2025.
  • Its last three reported values are $2000.0 in Q4 2025, $286000.0 for Q3 2025, and -$39000.0 during Q2 2025.